7articles were included. One study showed that in clinical practice, TCAs dispensations were maintained after the diagnosis of dementia. Two studies concluded that TCAs are the antidepressants least associated with the onset of dementia. In another study, the long-term use of TCAs was associated with a decrease in the incidence of dementia. A review by the Cochrane Group stated that the evidence on the safety of antidepressants in patients with dementia is of moderate quality, with little data from the antidepressant subgroups. The last two articles associated the use of antidepressants with dementia without differentiating the antidepressant groups. Conclusion and RelevanceBased on the data from our population, the high inappropriateness of TCAs prescription according to the STOPP criteria suggests that this is a field with ample room for improvement. PPIs could be reduced if STOPP criteria were computerised in electronic prescription programs. Since the results of the review are not consistent, we believe that the STOPP criteria regarding the use of TCAs in patients with dementia should be more flexible, assessing the benefit-risk of treatment on an individual basis and closely monitoring adverse effects.

3MPP is a useful treatment option for patients who are adequately treated with the 1 monthly formulation of paliperidone palmitate (PP) but who may benefit from longer dosing intervals. Aim and objectives To assess the appropriateness of 3MPP prescriptions and the effectiveness of treatment in our centre. Material and methods This was an observational retrospective study of patients with a 3MPP prescription between January 2018 and July 2020. The variables used to evaluate appropriateness were the number of switches from PP to 3MPP, dosage and administration time. Effectiveness was evaluated by recording treatment interruptions, dose variations and switch back to PP. Data were extracted from an administrative database and collected in Excel. Results 38 patients were included, 23 men (60.5%), with a mean age of 50±14 years. The dosages of 3MPP were: 175 mg in 5 patients (13.2%), 263 mg in 6 (15.8%), 350 mg in 18 (47.4%) and 525 mg in 9 (23.7%). In 30 patients (78.9%), the 3MPP prescription was appropriate. The number of switches was 35/38 (92.1%): 3 patients received a first prescription of 3MPP without a previous prescription of antipsychotic depot drugs from our centre. An appropriate dosage was selected in 33/35 patients (94.3%): 1 patient switched from PP 100 mg to 3MPP 263 mg and another from PP 150 mg to 3MPP 263 mg. An appropriate administration time was selected in 35/38 patients (92.1%): 1 patient took the drug every 4 months and two patients received only one administration of 3MPP. In total, six patients interrupted treatment (3 in 2019; 3 in 2020). Dose variation of 3MPP during treatment occurred in 2 patients: 1 switched from 3MPP 350 mg to 525 mg and the other from 3MPP 263 mg to 350 mg. Two patients returned to treatment with PP. Conclusion and relevance Most of the 3MPP prescriptions were appropriate. This treatment has been shown to be effective in this setting where clinical diagnosis and therapeutic choice are not simple and medication adherence is a clinical challenge. The intervention of the pharmacist by auditing prescriptions is important to further increase appropriate treatments in these patients.

p<0.001) and chemotherapy (12.6% vs 1.9%, p<0.001). Admission to the intensive care unit (ICU) was significantly more frequent in surgical patients (35.4% vs 10.9%, p<0.001) as well as use of second and third generation cephalosporins (30.0% vs 17.6%, p=0.001; 64.6% vs 53.1%, p=0.007, respectively). Conclusion and relevance Age !65 years, use of PPIs, chemotherapy and fluoroquinolones were positively associated with the medical group and were significant predictors of CDI, whereas admission to the ICU and the use of second and third generation cephalosporins were positively associated with being in the surgical group and were significant predictors of CDI. We conclude that medical patients were more endangered with HA CDI than surgical patients.

No abstract

psoriasis. Median age was 50.7 years (range 5.9-91.7) and 221 (61.9%) patients were men. 282 patients (79%) were treated with only one biological drug: 75 patients with anti-TNF-a, 132 with anti-IL-17 and 75 with anti-IL-23. 65 patients (18.2%) were treated with two biological drugs in sequence (table 1). Conclusion and relevance More than 97% of patients were treated with only one (79%) or two (18.2%) biological drugs for moderate-to-severe plaque psoriasis, with a prevalence of anti-IL-17. Further investigation of the causes for the change from one to another biological drug is needed. These could include adverse events, ineffectiveness or other reasons.